Here, we sought to test the hypothesis that the antitumor efficacy induced by the combinatorial use of BRAFi and VEGFA removal, BRAF/VEGFA targeting, correlates with the ability to induce an immune‐stimulatory milieu in a mouse syngeneic melanoma tumor model, derived from BRAF mutated murine cells. Here, VEGFA is linked to neoplasm.